Vilazodone: Clinical Basis for the US Food and Drug Administration’s Approval of a New Antidepressant
The DOI matches its Crossref record.
Abstract
Article Abstract Objective: Vilazodone was recently approved by the US Food and Drug Administration (FDA) for the treatment of major depressive disorder (MDD). The purpose of this review is to summarize the FDA's approach to its review of the clinical pharmacology and the clinical efficacy and safety data for this new drug application, important issues in its decision-making, and its conclusions. Data Sources: The data sources for this review were the original raw data sets for all clinical trials included in the development program for vilazodone, as well as the sponsor's original analyses of these data. Study Selection: Data were available from 24 human trials involving vilazodone, and included a total of 2,898 human subjects exposed to 1 or more doses of this drug. Data Extraction: The FDA had access to original raw data sets for these trials. Results: Vilazodone is effective in treating MDD at a dose of 40 mg/d, but it needs to be incrementally adjusted to this dose to minimize gastrointestinal symptoms. It needs to be taken with food to ensure adequate plasma concentrations. Vilazodone's profile of adverse events is similar to that seen with selective serotonin reuptake inhibitors. No dose adjustment is needed based on age, gender, or renal or hepatic impairment. It is recommended that the vilazodone dose be reduced to 20 mg when it is taken with strong cytochrome P450 (CYP) 3A4 inhibitors, eg, ketoconazole. Vilazodone is not expected to have important effects on the clearance of other drugs that are cytochrome P450 substrates. Conclusions: Vilazodone is a new treatment for MDD, but it is unknown whether it has any advantages compared to other drugs in the antidepressant class. J Clin Psychiatry 2011;72(9):1166-1173 © Copyright 2011 Physicians Postgraduate Press, Inc. Submitted: March 3, 2011; accepted April 29, 2011(doi:10.4088/JCP.11r06984). Corresponding author: Thomas P. Laughren, MD, Director, Division of Psychiatry Products, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993 (thomas.laughren@fda.hhs.gov).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., et al. (2016) · The Canadian Journal of Psychiatry · doi:10.1177/0706743716659417 · Cited by 1,181
Fava, M., Targum, S. D., Nierenberg, A. A., Bleicher, L. S., Carter, T. A., Wedel, P. C., Hen, R., Gage, F. H., & Barlow, C. (2012) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2012.08.013 · Cited by 67
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2015) · Psychiatry Investigation · doi:10.4306/pi.2015.12.2.155 · Cited by 36
Self-citationEvaluation of vilazodone for the treatment of depressive and anxiety disorders
Stuivenga, M., Giltay, E. J., Cools, O., Roosens, L., Neels, H., & Sabbe, B. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1549542 · Cited by 24
Metadata
- Authors
- Laughren, T. P., Gobburu, J., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., Fossom, L., Hung, H. M. J., Klimek, V., Lee, J. E., Levin, R. L., Lindberg, C. Y., Mathis, M., Rosloff, B. N., Wang, S.-J., Wang, Y., Yang, P., Yu, B., Zhang, H., Zhang, L., & Zineh, I.
- Venue
- The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2011-09-15
- Volume
- 72
- Issue
- 09
- Pages
- 1166-1173
- ISSN
- 0160-6689 (ISSN-L)
- OpenAlex
- W2078647070
- Cited by
- 226
- References
- 0
- FWCI
- 5.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Vilazodone: Clinical Basis for the US Food and Drug Administration’s Approval of a New Antidepressant. https://app.cochat.ai/papers/10.4088/jcp.11r06984
- The paper
- Laughren, T. P., Gobburu, J., Temple, R. J., Unger, E. F., Bhattaram, A., Dinh, P. V., Fossom, L., Hung, H. M. J., Klimek, V., Lee, J. E., Levin, R. L., Lindberg, C. Y., Mathis, M., Rosloff, B. N., Wang, S.-J., Wang, Y., Yang, P., Yu, B., Zhang, H., . . . Zineh, I. (2011). Vilazodone: Clinical Basis for the US Food and Drug Administration’s Approval of a New Antidepressant. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.11r06984
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.